Susquehanna International Group
ABCL icon

Susquehanna International Group’s AbCellera Biologics ABCL Stock Holding History

Susquehanna International Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.86M Buy
534,100
+197,300
+59% +$710K ﹤0.01% 6338
2025
Q4 		$1.15M Buy
336,800
+38,100
+13% +$170K ﹤0.01% 6868
2025
Q3 		$1.5M Buy
298,700
+65,400
+28% +$288K ﹤0.01% 6409
2025
Q2 		$800K Buy
233,300
+56,600
+32% +$141K ﹤0.01% 8015
2025
Q1 		$394K Buy
176,700
+10,400
+6% +$29.8K ﹤0.01% 9429
2024
Q4 		$487K Buy
166,300
+70,800
+74% +$197K ﹤0.01% 8725
2024
Q3 		$248K Sell
95,500
-38,800
-29% -$108K ﹤0.01% 10026
2024
Q2 		$398K Sell
134,300
-28,900
-18% -$109K ﹤0.01% 8808
2024
Q1 		$739K Sell
163,200
-18,100
-10% -$92.4K ﹤0.01% 7587
2023
Q4 		$1.04M Buy
181,300
+33,800
+23% +$157K ﹤0.01% 6917
2023
Q3 		$679K Sell
147,500
-79,500
-35% -$484K ﹤0.01% 7520
2023
Q2 		$1.47M Buy
227,000
+97,900
+76% +$668K ﹤0.01% 5819
2023
Q1 		$973K Sell
129,100
-95,900
-43% -$871K ﹤0.01% 6889
2022
Q4 		$2.28M Buy
225,000
+99,400
+79% +$1.15M ﹤0.01% 4479
2022
Q3 		$1.24M Sell
125,600
-19,700
-14% -$216K ﹤0.01% 6070
2022
Q2 		$1.55M Buy
145,300
+80,200
+123% +$679K ﹤0.01% 5449
2022
Q1 		$635K Sell
65,100
-269,500
-81% -$2.55M ﹤0.01% 8307
2021
Q4 		$4.79M Sell
334,600
-128,000
-28% -$1.94M ﹤0.01% 3817
2021
Q3 		$9.27M Buy
462,600
+162,800
+54% +$2.88M ﹤0.01% 2977
2021
Q2 		$6.6M Buy
299,800
+275,800
+1,149% +$7.61M ﹤0.01% 3527
2021
Q1 		$815K Buy
+24,000
New +$956K ﹤0.01% 8258

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's ABCL Position: Q1 2026 in Review

Susquehanna International Group reduced its AbCellera Biologics (ABCL) stake by 51% in Q1 2026, selling an estimated $2.79M and leaving 750,393 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #5561.

Susquehanna International Group first reported a position in ABCL in Q4 2020 and has held it in 21 quarters since. The position peaked at $8.71M in Q3 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Susquehanna International Group held 750,393 shares of AbCellera Biologics worth $2.62M as of Q1 2026.
  • Susquehanna International Group sold 774,170 AbCellera Biologics shares in Q1 2026, an estimated $2.79M.
  • AbCellera Biologics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5561 holding.
  • Susquehanna International Group first reported a position in AbCellera Biologics in Q4 2020 and has held it in 21 quarters since.
  • Susquehanna International Group's AbCellera Biologics position peaked at $8.71M in Q3 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.